JPRN-UMIN000033961已完成未知
Effectiveness and safety of Combination therapy of Ranibizumab and LuseOgliflozin in type 2 diabetes with diabetic Macular Edema, a parallel group comparison with the standard Treatment controlled by Glimepiride, multicenter, randomized, open-label trial. (COMET Trial) - Effectiveness and safety of Combination therapy of Ranibizumab and LuseOgliflozin in type 2 diabetes with diabetic Macular Edema, a parallel group comparison with the standard Treatment controlled by Glimepiride, multicenter, randomized, open-label trial. (COMET Trial)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who fall into any of the following criteria are excluded from participating in the study. <internal medicine> 1) patients with type 1 diabetes mellitus 2) patients with history of hypersensitivity against SGLT2 inhibitor or glimepiride 3) patients with history of coma or precoma due to the diabetes mellitus or hypoglycemia in the 24 weeks before the screening test 4) Patients with severe infections, before or after surgery, or severe trauma which require insulin treatment 5) Patients with severe renal dysfunction (eGFR < 30mL/ min/1.73m2), or patients who undergo dialysis (including peritoneal dialysis) 6) Female patients who are pregnant, possibly pregnant, or planned to be pregnant or breast feeding 7) Patients with urinary tract infection or dehydration, or patients who are prone to urinary tract infection or dehydration 8) Patients with positive urinary ketone body (urine qualitative of 2+ or higher) 9) Patients with history of leg amputation due to leg gangrene 10) Patients with history of bone fracture due to osteoporosis and others <ophthalmology> 16) patients with history of retina vitreal surgery or scleral buckling 17) Patients with history of filtration surgery to the study eye for glaucoma treatment, or patients who are expected to require the filtration surgery in future 18) Patients with active proliferative diabetic retinopathy in the study eye 19) Patients with history of idiopathic or autoimmune uveitis in the study eye 20) Patients with vitreomacular traction syndrome or epi-retinal membrane in the study eye measured by slit lamp microscope or OCT, which affect the central visual acuity and others <common> 35) Patients with other conditions that the investigator/researcher thinks inappropriate for the study <Due to the word limit in the UMIN-CTR, other exclusion criteria are described in the attached protocol>
研究者
相似试验
进行中（未招募）
不适用
COMET TrialJPRN-jRCTs031180210Yokote Koutaro60
已完成
不适用
The efficacy and safety of combination therapy of adoptive immunotherapy with chemotherapy for advanced pancreatic cancerJPRN-UMIN000011177Tokai University School of Medicine20
进行中（未招募）
1 期
Safety and efficacy of combination treatment with rituximab and leflunomide in patients with active rheumatoid arthritis - Rituximab and Leflunomide in RAEUCTR2005-004582-41-GBniversity of Leeds15
已完成
2 期
Efficacy and tolerability of combination therapy with aprepitant,palonosetron,and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy for gynecological cancer(Phase II Study)gynecological cancerJPRN-UMIN000003820Kansai Clinical Oncology Group -Gynecologic Cancer Group-100
已完成
不适用
A study on the efficacy of combination therapy of insulin and ipragliflozin in patients with type 2 diabetesJPRN-UMIN000014798Imamura clinic15